Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Woman Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Trial 2 to Assess MK-8342B Treatment Efficacy-Safety in Dysmenorrhea
In women with moderate to severe primary dysmenorrhea: 1. To evaluate the efficacy of the ENG-E2 vaginal ring relative to placebo in the treatment of dysmenorrhea at Treatment Cycle 2. 2. To a...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
A trial investigating how well pembrolizumab works in treating patients with relapsed or refractory Primary Mediastinal Large B-Cell Lymphoma Un ensayo de investigación de como funciona el pembrolizumab en el tratamiento de pacientes con linfoma mediastínico primario de linfocitos B grandes recidivante o resistente
To evaluate the Overall Response Rate (ORR) of pembrolizumab by independent central review according to the International Working Group (IWG) response criteria (Cheson, 2007) Evaluar la tasa de ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
MK-0518B EU Bioequivalence Study
To evaluate the comparative bioavailability between: •Raltegravir/lamivudine (MK-0518B) 300 mg/150 mg Fixed-Dose Combination (FDC) tablets from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Study to correlate a new biomarker (ST2) with clinical activity in Ulcerative Colitis patients under golimumab
- To evaluate the correlation of serum soluble ST2 levels with endoscopic activity (endoscopic Mayo score) at week 6 in moderate to severe UC subjects under golimumab treatment. - To evaluate the co...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Pembrolizumab as First Line Treatment in Subjects with Recurrent/Metastatic HNSCC
1) To compare the Progression Free Survival (PFS) per RECIST 1.1 as assessed by blinded independent central review (BICR) in a subgroup of first line recurrent/metastatic (R/M) head and neck squamous ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
EBR/GBR + SOF +/- RBV in Cirrhotic GT3 Subjects
(1) Objective: To evaluate the efficacy of each treatment arm of GZR/EBR (MK-5172A) in combination with Sofosbuvir (SOF) +/- Ribavirin (RBV) as assessed by the proportion of subjects achieving SVR12 (...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Ph 3 Placebo-Controlled Trial of Adjuvant MK-3475 in RCC Post Nephrectomy
To compare disease-free survival (DFS) as assessed by the investigator for participants treated with pembrolizumab versus those receiving placebo
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Effect of reversing muscle relaxation with sugammadex compared with usual care on bleeding risk in patients on blood thinners undergoing major joint surgery
To assess the effect of reversal of neuromuscular blockade with sugammadex 4 mg.kg-1 compared with reversal according to usual care (neostigmine or spontaneous reversal) on the incidence of adjudicate...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
A Phase III Study to Evaluate Chemotherapy With or Without Pembrolizumab as First Line Treatment for Triple Negative Breast Cancer
Part 1 (Safety Run-In): Objective: To evaluate the safety and tolerability of 3 pembrolizumab + chemotherapy combinations, namely, pembrolizumab + paclitaxel, pembrolizumab + nab paclitaxel, and pem...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
A Phase I/II trial of MK-3475 (pembrolizumab) in children’s solid tumors and lymphoma
(1) Objective: To define the rate of dose-limiting toxicities (DLTs) at the maximum tolerated dose (MTD) or maximum administered dose (MAD) of pembrolizumab when administered as monotherapy to child...
Country
None
organs
None
Specialty
None
More information
Previous
7
8
9
10
11
12
13
14
15
16
Next